Key result
Lipid-hostile antihypertensives were associated with higher median fibrinogen (383 mg/dL) compared with untreated (353 mg/dL) or lipid-neutral/friendly drugs (336 mg/dL; P<0.01).
Why the study?
Does the type of antihypertensive treatment affect cardiovascular risk biomarkers such as fibrinogen, lipoprotein(a), and bilirubin in patients with primary dyslipidemia?
Cross-Sectional (n=491)
Does the type of antihypertensive treatment affect cardiovascular risk biomarkers such as fibrinogen, lipoprotein(a), and bilirubin in patients with primary dyslipidemia?
Absolute Event Rate: 383% vs 353%
p-value: p=< .01
The choice of antihypertensive medication in patients with dyslipidemia influences additional cardiovascular risk factors, with lipid-hostile drugs increasing fibrinogen and lipid-neutral/friendly drugs lowering lipoprotein(a).
No takes yet. Share an insight, caveat, or question.
May support biomarker profiling for vascular risk in dyslipidemic hypertensives; leaves open predictive utility by treatment status.
John A. Papadakis (1999) conducted a cross-sectional in primary dyslipidemia (n=491). Antihypertensive treatment (lipid-hostile vs lipid-neutral/friendly) vs. Untreated hypertensives and normotensives was evaluated on Fibrinogen concentration (median mg/dL) (p=< .01). Lipid-hostile antihypertensives were associated with higher median fibrinogen (383 mg/dL) compared with untreated (353 mg/dL) or lipid-neutral/friendly drugs (336 mg/dL; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: